Creating neurotransformational medicines is our priority
We believe patients suffering from debilitating headache disorders and difficult-to-treat psychiatric disorders, no longer have to live this way
People with severe headaches deal with disabling pain that keeps them from working and participating in everyday life. Psychiatric sufferers, although not necessarily suffering from pain, are also limited in their ability to lead regular lives and often experience psychological despair.
Both groups agonize due to few medical alternatives, making them feel hopeless as their medical needs continue to be unmet. In addition, they carry the burden of their isolation and miss out on raising their children and being with family and community. They also feel different and separate from others because of their disorder and are often viewed as “freaks” in severe cases or “making it up” in more mild ones.
For too long, they have been poorly understood and under-served.
At Ceruvia Lifesciences, we get it and are doing something about it.
We seek opportunities to create neurotransformational medical breakthroughs for these two disorders, amongst many, with our products.
Since 2017, Ceruvia Lifesciences, founded by Carey Turnbull, has relentlessly focused on the discovery, development, and commercialization of transformational medicines to deliver meaningful relief to patients suffering from these hard-to-treat headache and psychiatric disorders.
Seeking opportunities to create new transformational medical breakthroughs
Create significant health impact by providing targeted funding that focuses on providing relief to marginalized sufferers and ultimately making a difference in millions of people’s lives.
We fill a significant gap in the psychedelic and related drug industry (>$1.2bn/annum) that current organizations do not pursue, positioning us as leaders in this space.
Continue to generate data from controlled clinical trials in academic settings at leading institutions.
We fund and work with innovative collaborators and partners to discover and develop promising medicines to treat challenging disorders.
Ceruvia Lifesciences is built on sound science and has gathered key, experienced consultants and scientific advisors to advance projects.
We are the world’s first producers of GMP LSD, which we supply to academic research sites, and GMP BOL-148.
We adhere to the highest development, testing, and manufacturing standards as established by regulatory authorities as well as pharmaceutical industry associations and organizations.
We envision a future where Ceruvia Lifesciences can deploy treatments to create a significant benefit for all stakeholders in our focus areas: patients, caregivers, payers, and health care providers.
A Word from Our Founder & CEO
Ceruvia Lifesciences’ project is to make psilocybin, and related compounds approved medications for headache disorders.
As such, we promote medical research on cluster headache and migraine, working closely with the patient advocacy group Clusterbusters, a knowledgeable advisor we admire for their years of hard work, expertise, and advice. But with the proviso, Ceruvia cannot encourage the use of psilocybin outside of an approved and regulated medical setting.
We hope to add value to that community and ease its suffering within that context.
Meet Our Veteran Team
10+ years Investment/ Philanthropy in Psychedelic Medicine
20+ years Pharmaceutical Project Management
Judy Ashworth, MD
Chief Medical Officer
20+ years Analgesic & CNS Drug Development
Chief Scientific Officer
40+ years Quality Assurance & CMC Development
Stephan Loose, MBA
Chief Commercial Officer
15+ years Pharmaceutical Commercialization & Business Development
Global Project Lead
20+ years Drug Development
Board of Directors
Stephen Hurst has over thirty-five years’ experience in the biopharmaceutical industry, including in senior executive positions at Sequential, Inc. and Inhale Therapeutic Systems, Inc., (now Nektar Therapeutics, Inc.), where he played a pivotal role in raising over $700 million in investment capital. In addition to formerly serving as a consultant to the World Bank and BIO Venture for Global Health, Hurst most recently served as co-CEO of Mind Medicine, a psychedelic pharmaceutical company he co-founded in 2019. From 2011 to 2019, Hurst served as CEO of Savant HWP, which he co-founded and oversaw the development and testing of psychedelic-based treatments to address substance use disorders.
David Steinberg has over twenty-five years’ experience on Wall Street as a top-ranked equity research analyst following the specialty pharmaceuticals industry. Prior to being appointed CFO at Prolacta Bioscience earlier this year, David served as Managing Director at Jefferies LLC and Deutsche Bank. He has regularly been voted by portfolio managers to the Institutional Investor “All America Research Team.” Most recently he was ranked #2 in the sector for 2021 and has been recognized as a top stock picker by surveys such as The Wall Street Journal’s “Best on the Street.” David also has deep capital markets experience and was instrumental in helping launch over 50 successful pharmaceutical and biotechnology IPOs, while also assisting entrepreneurial
companies raise over $25 billion in equity and equity linked securities during his career.
Meet Our Collaborators and Partnerships
Since 2015, Yale University has been the site of Ceruvia Lifesciences’ research to treat Cluster Headache, Migraines, and OCD and and is key to our life science efforts.
Cluster Headache and Migraine Research: Lead by D. Cyril D’Souza, M.D., Professor of Psychiatry and Chris Gottschalk, M.D., Director of Headache & Facial Pain Center, and conducted by Emmanuelle Schindler, M.D., Ph.D., Assistant Professor of Neurology
OCD Research: Conducted by Chris Pittenger, M.D., Professor of Psychiatry, and Ben Kelmendi, M.D, Assistant Professor of Psychiatry.
Usona Institute is a non-profit medical research organization dedicated to supporting and conducting pre-clinical and clinical research to understand further the therapeutic effects of psilocybin and other consciousness-expanding medicines. Their focus is on alleviating depression in people whose current medical treatments fall short in offering relief and a better quality of life.
Usona has manufactured pharmaceutical-grade psilocybin and is currently conducting the necessary comprehensive pre-clinical toxicology work for prescription medication, enabling Ceruvia Lifesciences’ FDA clinical trials.
The Heffter Research Institute promotes the highest-quality scientific research with classic hallucinogens and related compounds (sometimes called psychedelics) to better understand how the mind improves the human condition and alleviates suffering.
Ceruvia Lifesciences seeks to take academic research Heffter has been instrumental in developing at elite universities and pivot it into prescription medication development trials required by FDA.
New York University (NYU), one of the nation’s premier academic medical centers, has newly created the NYU Langone Center for Psychedelic Medicine, which conducts trials for Ceruvia Lifesciences focusing on substance abuse disorder research.
Clusterbusters is a patient advocacy group that supports research for better headache disorders treatments while advocating to improve the lives of those struggling with cluster headaches. For the past ten years, their advocacy has been an essential tool for Ceruvia Lifesciences programs.